Home Stroke Youths Day Out – Brain Tumour Society (Singapore) Ltd.

Youths Day Out – Brain Tumour Society (Singapore) Ltd.

21 November 2020 marked BTSS first youths’ outing at Jewel Changi Airport.  Adhering to the current COVID19 restrictions on social gatherings, the 10 youths were split into 2 groups and led by Qin Han and Leonard.  After meeting up at Changi Airport MRT station, the 2 groups proceeded to the Canopy Park at Jewel.  Canopy Park, as well as, the rest of Jewel, was decked in Christmas decorations which added wondrous festive cheer.  The youths explored the various attractions in Canopy Park in their own groups, and then proceeded for lunch after much walking.  Time passed fast and before long, the youths had to say goodbye to one another.

(We hope this is the first of many more outings for our youths, and we hope they find strength in one another and build lasting friendships.)

 



Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Women of Minority Race/Ethnicity, Lower Socioeconomic Status Experience Lower Digital Breast Tomosynthesis Access

A cross-sectional study of digital breast tomosynthesis (DBT) screening published in JAMA Network Open indicated that women of minority race/ethnicity and lower socioeconomic status...

Michael Szarek, PhD, on the Outcomes of a Q-TWiST Analysis From the Phase 3 TIVO-3 Study

An analysis revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in...

Recent Comments